Blog

Hua Medicine Successfully Completes Initial Public Offering and Listing on the Hong Kong Stock Exchange

Hong Kong, September 14, 2018

Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.

The IPO priced at HK$8.28 per share, with a total offering size of 104,756,000 shares, before over-allotments, raising approximately HK$867 million with a market capitalization of approximately HK$8,710 million immediately after the IPO.

The Global Sponsors for the IPO were Goldman Sachs (Asia) L.L.C. and CLSA Capital Markets Limited, the Joint Bookrunners were Goldman Sachs (Asia) L.L.C., CLSA Limited and UBS AG Hong Kong Branch and the Joint Lead Managers were Goldman Sachs (Asia) L.L.C, CLSA Limited, UBS AG Hong Kong Branch and Guotai Junan Securities (Hong Kong) Limited.

Read more

Iora Health and Humana Expand Relationship to Provide More Humana Medicare Advantage Plan Members Access to Improved Care in Arizona, Georgia and Washington

BOSTON & LOUISVILLE, Ky. — Humana Medicare Advantage beneficiaries have additional access to high-impact, relationship-based primary care thanks to Iora Health and Humana Inc. (NYSE: HUM) teaming up for the fifth year to add 10 additional Iora Primary Care practices to Humana’s Medicare Advantage Plan network in Arizona, Georgia and Washington.

Iora Health and Humana’s value-based relationship is already delivering on the promise to provide a high quality of care and service to older adults in Arizona, Colorado and Washington. This year, new practices are opening in Tacoma, Washington; Tucson and Phoenix, Arizona; and, for the first time, Atlanta, Georgia.

The new practices provide patients with Humana Medicare Advantage access to Iora’s model of care that changes the way primary care is delivered. By investing more in preventive care, building robust care teams, focusing on health outcomes, increasing customer service and incorporating proprietary technology built to support this unique care, Iora is leading the charge to transform the industry. Iora Primary Care patients experience:

Read More

Innovent doses first patient in Phase III sintilimab trial for NSCLC

China-based biopharmaceutical company Innovent Biologics has dosed the first patient in the Phase III ORIENT-11 trial designed to evaluate sintilimab (IBI308) as first-line treatment for patients with non-squamous non-small cell lung cancer (NSCLC).

The randomised, double-blinded, multicentre trial intends to study sintilimab or placebo along with pemetrexed and platinum-based chemotherapy as first-line treatment to advanced or ns-NSCLC patients in China.

The trial is currently treating patients with the study drug combination in four cycles, followed by a maintenance treatment of sintilimab or placebo in combination with pemetrexed until the first occurrence of disease progression, intolerable toxicity, withdrawal of consent, death, or other specified events of the trial.

Read more

Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

FOSTER CITY, Calif. & DURHAM, N.C.–(BUSINESS WIRE)–Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.

An estimated 257 million people are living with HBV infection around the world. Current HBV treatments suppress HBV viral replication but do not completely clear the virus. The presence of covalently closed circular DNA (cccDNA) enables HBV replication if treatment is stopped. Preliminary studies at Gilead using ARCUS nucleases to target HBV cccDNA in vitro have demonstrated significant activity against cccDNA and integrated HBV DNA in human hepatocytes.

“Gilead is committed to developing innovative therapies to achieve functional cure for patients with chronic hepatitis B virus infection,” said John McHutchison, MD, Chief Scientific Officer and Head of Research and Development at Gilead. “We are excited about the potential of genome editing and Precision’s ARCUS technology, which has demonstrated promising in vitro activity. We look forward to exploring this technology as an important component of our HBV cure research efforts.”

Read more

RiskRecon and Whistic Announce Partnership

SALT LAKE CITY /PRNewswire/ — RiskRecon, the fastest-growing company transforming management of third-party cyber risk, today announced a partnership with Whistic, a leading vendor assessment platform that enables companies to conduct and respond to security reviews on a single platform. The alliance will allow companies to quickly tackle and respond to common risk assessment and review process challenges, increasing third-party visibility to make more informed risk decisions.

Built for companies focused on pro-actively managing security reviews and responding to security questionnaires, Whistic enhances evaluation of third-party vendor networks while improving the process of gathering, sending, receiving, and sharing assessment information across business units. The partnership will enable joint customers of Whistic and RiskRecon to manage the vendor assessment lifecycle end-to-end, obtaining a verifiable assessment of third-party cyber security practices for a 360-degree view of vendor risk.

“Partnering with Whistic provides our joint customers with a one-stop solution for reducing third-party cyber risk,” said Eric Blatte, President and Co-founder of RiskRecon. “Together, we’re able to deliver the kind of dynamic insights that help customers rapidly identify and understand the security posture of their third-party relationships and most importantly, act on that risk.”

Read More

OTA Insight honoured as ‘One to Watch’ in Sunday Times Tech Track 100

LONDON and NEW YORK /PRNewswire/ — OTA Insight, the cloud-based data intelligence platform for the hospitality industry, today announced it was named one of 10 “Ones to Watch” in the 18th annual The Sunday Times Tech Track 100. The Sunday Times Hiscox Tech Track 100 league table ranks Britain’s 100 private tech (TMT) companies with the fastest-growing sales over their latest three years. The results are compiled by Fast Track, the Oxford-based research and networking events firm. Results are published in The Sunday Times every September.

“We are thrilled to be recognised by the The Sunday Times Tech Track 100 as ‘One to Watch,'” said Sean Fitzpatrick, CEO of OTA Insight. “This honour validates our exceptional success and innovation, driven by a combination of our team’s hard work and unique abilities, as well as our incredibly creative, collaborative company culture. We have no doubt that OTA Insight is primed to become the global leader in hospitality business intelligence with our continued growth.”

This latest achievement follows OTA Insight being named one of “The 10 Most Valued Business Intelligence Companies” by Analytics Insight, the leading data analytics website and publication. Earlier this year, OTA Insight was also nominated as one of the Best Technology Innovators at the annual HSMAI Europe Awards Ceremony.

Read More

Unum Therapeutics to Present at Morgan Stanley 16th Annual Global Healthcare Conference

CAMBRIDGE, Mass., (GLOBE NEWSWIRE) — Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T cell Receptor (ACTR) technology platform, will present a corporate overview in a fireside chat with Charles Wilson, Chief Executive Officer, at the Morgan Stanley 16th Annual Global Healthcare Conference on Friday, September 14, 2018 at 9:20 a.m. ET in New York City.

The presentation will be webcast live, and available for replay on the “Events” section of Unum’s investor relations webpage (investors.unumrx.com/events) where it will be archived for approximately 90 days.

Read More

 

Innovent’s Anti-CD47 Antibody IBI188 Receives IND Approval in China

SUZHOU, China /PRNewswire/ — Innovent Biologics (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today announced that its IND application for IBI188, a fully human anti-CD47 monoclonal antibody (mAb) drug candidate, has been approved by the National Medical Products Administration (NMPA, formerly known as CFDA) for clinical trials. Innovent will launch several clinical trials based on this mAb drug to assess its safety and efficacy for multiple tumor types, including non-Hodgkin’s lymphoma and ovarian cancer. This is the fourth IND approval the company has received this year, including anti-CTLA-4 mAb, anti-RANKL mAb, anti-OX40 mAb and anti-CD47 mAb.

As one of the key targets in the field of anti-tumor immunotherapy, CD47 is regarded by many experts to have the possibility of becoming the next “star” in the field of immuno-oncology following the ground-breaking success of PD1 / PD-L1 antibodies. The IND approval signals that Innovent’s discovery and development on CD47 has advanced IBI188 as a leading player for this target to enter into clinical development stage.

“Innovent, with a relentless focus on innovation and quality, has developed programs that are advancing into cutting edge drug development frontiers. We hope that through our efforts, we can advance the field of cancer treatment, provide better treatment options to increase patients’ survival rate and improve their quality of life,” said Michael Yu, Founder, Chief Executive Officer and Chairman.

Read More

Flywire Executives Featured at Boston FinTech Week

BOSTON, Sept. 05, 2018 (GLOBE NEWSWIRE) — Flywire, a company that solves complex payment problems for leading businesses and institutions, will participate in Boston FinTech Week, taking place around the city from September 10-14. CEO Mike Massaro and Chief Compliance Officer and General Counsel, Peter Butterfield will both be part of events during the week.

Boston FinTech Week, organized by FinTech Sandbox, is a collaboration between Boston’s accelerators, institutions, startups, universities, firms, co-working spaces and individuals designed to galvanize the local fintech ecosystem. It includes workshops, panels, crash courses, fireside chats, speed dating and more. The events take place at venues across the city and are all free.

Read more

Notable Health Closes $13.5 Million Series A Financing to Expand Artificial Intelligence Powered Physician-Patient Interaction Platform

SAN MATEO, Calif.–Notable Health, an artificial intelligence (AI) powered health care company that automates and digitizes physician-patient interactions, today announced it has closed $13.5 million in a Series A funding round. The financing round includes many of the best-known venture firms investing in innovative companies in digital health. The round was led by F-Prime Capital Partners and Oak HC/FT with participation from existing investors Greylock Partners and Maverick Ventures. F-Prime Capital Partners’ General Partner Carl Byers will join Notable Health’s Board of Directors and Oak HC/FT Managing Partner Annie Lamont will serve as a Board Observer.

Notable Health’s AI technology is addressing a long-standing challenge that physicians encounter when updating electronic health records (EHR) by having them speak directly into their Apple smartwatch rather than a PC or tablet – which can be difficult to work with, interfere with patient interaction, along with information often being captured incorrectly. Physicians using Notable Health are saving 70 minutes and 1000 clicks per day allowing them to schedule additional patient appointments resulting in a 15-20% increase in revenues, on average.

“Notable Health was founded with the mission of enriching every physician-patient interaction by eliminating the drudgery of administrative tasks and improving data quality. Through the use of continually-learning AI, voice recognition, and wearables we’re empowering physicians to be more productive and improve patient outcomes,” said Pranay Kapadia, Co-Founder and CEO. “We are thrilled to partner with some of the industry’s leading digital health investors as we continue to expand our product development and accelerate hiring across the company. We feel by addressing the traditional charting methods physicians currently use in their EHRs, Notable Health is in a unique position to help physicians operate more efficiently, see more patients, and help the industry continue to move to a more outcomes-based model.”

Read More